Virtual Library
Start Your Search
T. Kimura
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-007 - Prognostic Factors including EGFR Status in Advanced Lung Adenocarcinoma Patients (ID 975)
09:30 - 09:30 | Author(s): T. Kimura
- Abstract
Background:
Disease stage and performance status (PS) are the most widely accepted prognostic factors of non-small cell lung carcinoma. Several other features such as sex, age, histology, and health related quality of life (HRQOL) have also been reported as prognostic factors. Adenocarcinoma, especially EGFR mutation status, influences therapeutic strategy and prognosis. However, there have been few studies evaluating prognostic factors including activating EGFR mutation status focused on lung adenocarcinoma. This study aimed to clarify prognostic factors including EGFR status in advanced lung adenocarcinoma.
Methods:
From April 2010 to December 2014, patients diagnosed with lung adenocarcinoma were identified retrospectively. Stage ⅢB, StageⅣ and recurrent post-operative patients were included. A total of 95 patients with adenocarcinoma who was measured EGFR mutation status and completed the overall health related quality of life (HRQOL) item before receiving initial cytotoxic chemotherapy were included in the analysis. We evaluated HRQOL using EORTC QOL-C30 and LC-13 (European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire). The activating EGFR mutations consist of a deletion in exon 19 and a point mutation involving the replacement of leucine with arginine at codon 858 (L858R) in exon 21. EGFR mutation status, HRQOL scales, PS, age, sex, stage, data on Charlson comorbidity index, pulmonary function testing, and serum levels of white blood cells, haemoglobin, fibrinogen, calcium, alkaline phosphatases, lactate dehydrogenase were included in univariate and multivariate Cox proportional hazard analyses.
Results:
The median age was 67 years. Sixty one patients were men. Five patients had stage ⅢB , 76 had stage Ⅳand 14 were recurrent post-operative cases. Thirty two patients had activating EGFR mutation. Median survival time was 556 days. Global health status, Physical functioning, Role functioning, Social functioning, Fatigue scales of EORTC QOL-C30, Coughing scales of LC-13, EGFR mutation status, PS, Stage and serum levels of white blood cells, fibrinogen and albumin were associated with poor prognosis in univariate analyses. On multivariate analysis, Role functioning (HR: 0.988, 95% CI: 0.979-0.997), activating EGFR mutation (HR: 2.621, 95% CI: 1.401-4.906), female sex (HR: 2.158, 95% CI: 1.118-4.163) and stage (HR: 0.213, 95% CI: 0.090-0.501) were significantly predictors of survival.
Conclusion:
EGFR mutation status, Role functioning, sex and stage are significant and independent prognostic factors for survival in patients with advanced lung adenocarcinoma.
